NASDAQ
Acrivon Therapeutics, Inc. (ACRV)
♥ 711 Thanks from members
Acrivon Therapeutics (ACRV) exhibits a stark divergence between promising clinical data—such as a 52% to 67% response rate in biomarker-positive endometrial cancer for ACR-368—and heavy market discounting, leaving it trading near or below cash value.